Deakin University
Browse

File(s) under permanent embargo

Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas

journal contribution
posted on 1998-02-01, 00:00 authored by G B McCowage, H S Friedman, A Moghrabi, T Kerby, L Ferrell, E Stewart, M Duncan-Brown, H E Fuchs, R Tien, R E McLendon, L Meier, J Kurtzberg, David Ashley, O M Colvin, D C Longee
Seventeen patients less than or equal to 20 years of age with newly diagnosed (n = 10) or recurrent (n = 7) malignant gliomas (anaplastic astrocytoma and glioblastoma multiforme) were treated with cyclophosphamide in association with hematopoietic cytokines (GM-CSF or G-CSF). Cyclophosphamide was given at a dose of 2 g/m2 daily for 2 days at 4-week intervals. Toxicity consisted of grade IV neutropenia and thrombocytopenia in 95% and 48% of cycles, respectively. There were no cyclophosphamide-related cardiac, pulmonary, or urothelial toxicities observed. Four of 10 patients with newly diagnosed disease demonstrated responses (three complete and one partial responses; one CR was only of 2 months duration). None of the seven patients with recurrent tumors demonstrated a response. We conclude that high-dose cyclophosphamide warrants further evaluation in children with newly diagnosed malignant glioma.

History

Journal

Medical pediatric oncology

Volume

30

Issue

2

Pagination

75 - 80

Publisher

John Wiley & Sons

Location

Chichester, Eng.

ISSN

0098-1532

Language

eng

Publication classification

CN.1 Other journal article

Copyright notice

1998, Wiley-Liss